首页> 外国专利> ASSESSING RESPONSIVENESS OF RHEUMATOID ARTHRITIS PATIENTS TO BIOLOGICAL TREATMENT

ASSESSING RESPONSIVENESS OF RHEUMATOID ARTHRITIS PATIENTS TO BIOLOGICAL TREATMENT

机译:评估类风湿关节炎患者对生物治疗的反应

摘要

The relates to the field of diagnosis and treatment of Rheumatoid Arthritis, in particular of assessing responsiveness of rheumatoid arthritis patients to biological treatment. In particular the it has been found that measurement of MDR1 and/or MRP1 transport activities in the early phase of or before a bDMARD treatment is appropriate to provide a prediction on the effectiveness or success of bDMARD therapy once csDMARD therapy has failed. Thus, the invention relates to an in vitro diagnostic method for assessing the responsiveness of a sDMARD treated RA patient to bDMARD therapy, wherein preferably the patient is in need of a switch or modification of the sDMARD therapy by measuring transport activities of the above-mention transporters or their composite activities. The invention also relates to use of kits for the methods of the invention and methods for treatment comprising the diagnosis or prediction of the invention.
机译:本发明涉及类风湿关节炎的诊断和治疗领域,特别是评估类风湿关节炎患者对生物治疗的反应性。特别地,已经发现,在bDMARD治疗的早期或之前,对mDR1和/或MRP1转运活性的测量适于提供一旦csDMARD治疗失败后bDMARD治疗的有效性或成功的预测。因此,本发明涉及用于评估经sDMARD治疗的RA患者对bDMARD疗法的反应性的体外诊断方法,其中优选地,该患者需要通过测量上述提及的转运活性来改变或修改sDMARD疗法。运输者或其复合活动。本发明还涉及用于本发明方法的试剂盒的用途以及包括本发明的诊断或预测的治疗方法。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号